表紙:片頭痛治療薬の世界市場 - 市場シェア・規模・動向・業界分析:製品タイプ別、治療クラス別、投与経路別、最終用途別、地域別、セグメント予測(2022年~2030年)
市場調査レポート
商品コード
1150079

片頭痛治療薬の世界市場 - 市場シェア・規模・動向・業界分析:製品タイプ別、治療クラス別、投与経路別、最終用途別、地域別、セグメント予測(2022年~2030年)

Migraine Drugs Market Share, Size, Trends, Industry Analysis Report, By Product Type (Acute/Abortive Treatment, Preventive/Prophylactic Treatment); By Therapeutic Class; By Route of Administration; By End-Use; By Region; Segment Forecast, 2022 - 2030

出版日: | 発行: Polaris Market Research | ページ情報: 英文 118 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.08円
片頭痛治療薬の世界市場 - 市場シェア・規模・動向・業界分析:製品タイプ別、治療クラス別、投与経路別、最終用途別、地域別、セグメント予測(2022年~2030年)
出版日: 2022年10月01日
発行: Polaris Market Research
ページ情報: 英文 118 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の片頭痛治療薬の市場規模は、2030年までに87億9,000万米ドルに達すると予測されています。

当レポートでは、世界の片頭痛治療薬市場を調査しており、市場の概要、市場規模や予測、動向、促進要因・抑制要因、製品タイプ別・治療クラス別・投与経路別・最終用途別・地域別などの分析、さらに企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

  • レポートの説明
    • 調査の目的
    • 市場範囲
    • 前提条件
  • 利害関係者

第2章 エグゼクティブサマリー

  • 市場のハイライト

第3章 調査手法

  • 概要
    • データマイニング
  • 情報源
    • 一次情報
    • 二次情報

第4章 世界の片頭痛治療薬市場の洞察

  • 片頭痛治療薬 - 業界のスナップショット
  • 片頭痛治療薬市場力学
    • 促進要因と機会
    • 抑制要因と課題
  • ポーターのファイブフォース分析
    • 供給企業の交渉力
    • 新規参入者の脅威
    • 買い手の交渉力
    • 代替品の脅威
    • 既存企業間の競争力
  • PESTLE分析
  • 片頭痛治療薬業界の動向
  • バリューチェーン分析
  • COVID-19影響分析

第5章 世界の片頭痛治療薬市場:製品タイプ別

  • 主な調査結果
  • イントロダクション
    • 世界の片頭痛治療薬市場、製品タイプ別(2018年~2030年)
  • 急性治療薬/頓挫薬
    • 世界の片頭痛治療薬市場、急性治療薬/頓挫薬、地域別(2018年~2030年)
  • 予防薬/予防治療薬
    • 世界の片頭痛治療薬市場、予防薬/予防治療薬別、地域別(2018年~2030年)

第6章 世界の片頭痛治療薬市場:治療クラス別

  • 主な調査結果
  • イントロダクション
    • 世界の片頭痛治療薬市場、治療クラス別(2018年~2030年)
  • トリプタン
    • 世界の片頭痛治療薬市場、トリプタン別、地域別(2018年~2030年)
  • アセチルコリン阻害剤/神経毒
    • 世界の片頭痛治療薬市場、アセチルコリン阻害剤/神経毒別、地域別(2018年~2030年)
  • 麦角アルカロイド
    • 世界の片頭痛治療薬市場、麦角アルカロイド別、地域別(2018年~2030年)
  • NSAID
    • 世界の片頭痛治療薬市場、NSAID別、地域別(2018年~2030年)
  • ジタン
    • 世界の片頭痛治療薬市場、ジタン別、地域別(2018年~2030年)
  • CGRP低分子アンタゴニスト
    • 世界の片頭痛治療薬市場、CGRP低分子アンタゴニスト別、地域別(2018年~2030年)
  • CGRPモノクローナル抗体
    • 世界の片頭痛治療薬市場、CGRPモノクローナル抗体別、地域別(2018年~2030年)
  • その他
    • 世界の片頭痛治療薬市場、その他別、地域別(2018年~2030年)

第7章 世界の片頭痛治療薬市場:投与経路別

  • 主な調査結果
  • イントロダクション
    • 世界の片頭痛治療薬市場、投与経路別(2018年~2030年)
  • 経口
    • 世界の片頭痛治療薬市場、経口別、地域別(2018年~2030年)
  • 注射
    • 世界の片頭痛治療薬市場、注射別、地域別(2018年~2030年)
  • その他
    • 世界の片頭痛治療薬市場、その他別、地域別(2018年~2030年)

第8章 世界の片頭痛治療薬市場:最終用途別

  • 主な調査結果
  • イントロダクション
    • 世界の片頭痛治療薬市場、最終用途別(2018年~2030年)
  • 病院薬局
    • 世界の片頭痛治療薬市場、病院薬局別、地域別(2018年~2030年)
  • 小売薬局
    • 世界の片頭痛治療薬市場、小売薬局別、地域別(2018年~2030年)
  • オンライン薬局
    • 世界の片頭痛治療薬市場、オンライン薬局別、地域別(2018年~2030年)

第9章 世界の片頭痛治療薬市場:地域別

  • 主な調査結果
  • イントロダクション
    • 片頭痛治療薬市場の評価、地域別(2018年~2030年)
  • 片頭痛治療薬市場 - 北米
    • 北米:片頭痛治療薬市場、製品タイプ別(2018年~2030年)
    • 北米:片頭痛治療薬市場、最終用途別(2018年~2030年)
    • 北米:片頭痛治療薬市場、治療クラス別(2018年~2030年)
    • 北米:片頭痛治療薬市場、投与経路別(2018年~2030年)
    • 片頭痛治療薬市場 - 米国
    • 片頭痛治療薬市場 - カナダ
  • 片頭痛治療薬市場 - 欧州
    • 欧州:片頭痛治療薬市場、製品タイプ別(2018年~2030年)
    • 欧州:片頭痛治療薬市場、最終用途別(2018年~2030年)
    • 欧州:片頭痛治療薬市場、治療クラス別(2018年~2030年)
    • 欧州:片頭痛治療薬市場、投与経路別(2018年~2030年)
    • 片頭痛治療薬市場 - 英国
    • 片頭痛治療薬市場 - フランス
    • 片頭痛治療薬市場 - ドイツ
    • 片頭痛治療薬市場 - イタリア
    • 片頭痛治療薬市場 - スペイン
    • 片頭痛治療薬市場 - オランダ
    • 片頭痛治療薬市場 - ロシア
  • 片頭痛治療薬市場 - アジア太平洋
    • アジア太平洋:片頭痛治療薬市場、製品タイプ別(2018年~2030年)
    • アジア太平洋:片頭痛治療薬市場、最終用途別(2018年~2030年)
    • アジア太平洋:片頭痛治療薬市場、治療クラス別(2018年~2030年)
    • アジア太平洋:片頭痛治療薬市場、投与経路別(2018年~2030年)
    • 片頭痛治療薬市場 - 中国
    • 片頭痛治療薬市場 - インド
    • 片頭痛治療薬市場 - 日本
    • 片頭痛治療薬市場 - マレーシア
    • 片頭痛治療薬市場 - インドネシア
    • 片頭痛治療薬市場 - 韓国
  • 片頭痛治療薬市場 - 中東・アフリカ
    • 中東・アフリカ:片頭痛治療薬市場、製品タイプ別(2018年~2030年)
    • 中東・アフリカ:片頭痛治療薬市場、最終用途別(2018年~2030年)
    • 中東・アフリカ:片頭痛治療薬市場、治療クラス別(2018年~2030年)
    • 中東・アフリカ:片頭痛治療薬市場、投与経路別(2018年~2030年)
    • 片頭痛治療薬市場 - サウジアラビア
    • 片頭痛治療薬市場 - 南アフリカ
    • 片頭痛治療薬市場 - イスラエル
    • 片頭痛治療薬市場 - アラブ首長国連邦
  • 片頭痛治療薬市場 - ラテンアメリカ
    • ラテンアメリカ:片頭痛治療薬市場、製品タイプ別、2018年から2030年
    • ラテンアメリカ:片頭痛治療薬市場、最終用途別(2018年~2030年)
    • ラテンアメリカ:片頭痛治療薬市場、治療クラス別(2018年~2030年)
    • ラテンアメリカ:片頭痛治療薬市場、投与経路別(2018年~2030年)
    • 片頭痛治療薬市場 - メキシコ
    • 片頭痛治療薬市場 - ブラジル
    • 片頭痛治療薬市場 - アルゼンチン

第10章 競合情勢

  • 拡大・買収の分析
    • 拡大
    • 買収
  • パートナーシップ/コラボレーション/協定/公開

第11章 企業プロファイル

  • Allergan Plc
  • Alder Biopharmaceuticals Inc.
  • AstraZeneca PLC
  • Amgen Inc
  • eNeura Inc
  • Endo Pharmaceuticals Inc
  • Eli Lilly and Company
  • GlaxoSmithKline Plc
  • Johnson & Johnson Services Inc
  • Merck & Co. Inc
  • Pfizer Inc
  • Teva Pharmaceutical Industries Ltd
図表

List of Tables

  • Table 1 Global Migraine Drugs Market, by Product Type, by Region, 2018 - 2030 (USD Billion)
  • Table 2 Global Migraine Drugs Market, by Therapeutic Class, by Region, 2018 - 2030 (USD Billion)
  • Table 3 Global Migraine Drugs Market, by Route of Administration, by Region, 2018 - 2030 (USD Billion)
  • Table 4 Global Migraine Drugs Market, by End-Use, by Region, 2018 - 2030 (USD Billion)
  • Table 5 Migraine Drugs Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • Table 6 North America: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 7 North America: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 8 North America: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 9 North America: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 10 U.S.: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 11 U.S.: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 12 U.S.: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 13 U.S.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 14 Canada: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 15 Canada: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 16 Canada: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 17 Canada: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 18 Europe: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 19 Europe: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 20 Europe: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 21 Europe: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 22 Germany: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 23 Germany: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 24 Germany: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 25 Germany: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 26 France: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 27 France: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 28 France: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 29 France: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 30 UK: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 31 UK: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 32 UK: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 33 UK: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 34 Italy: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 35 Italy: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 36 Italy: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 37 Italy: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 38 Netherlands: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 39 Netherlands: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 40 Netherlands: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 41 Netherlands: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 42 Spain: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 43 Spain: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 44 Spain: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 45 Spain: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 46 Russia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 47 Russia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 48 Russia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 49 Russia: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 50 Asia Pacific: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 51 Asia Pacific: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 52 Asia Pacific: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 53 Asia Pacific: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 54 China: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 55 China: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 56 China: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 57 China: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 58 Japan: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 59 Japan: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 60 Japan: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 61 Japan: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 62 India: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 63 India: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 64 India: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 65 India: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 66 Indonesia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 67 Indonesia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 68 Indonesia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 69 Indonesia: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 70 Malaysia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 71 Malaysia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 72 Malaysia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 73 Malaysia: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 74 South Korea: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 75 South Korea: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 76 South Korea: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 77 South Korea: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 78 Latin America: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 79 Latin America: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 80 Latin America: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 81 Latin America: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 82 Brazil: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 83 Brazil: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 84 Brazil: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 85 Brazil: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 86 Mexico: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 87 Mexico: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 88 Mexico: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 89 Mexico: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 90 Argentina: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 91 Argentina: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 92 Argentina: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 93 Argentina: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 94 Middle East & Africa: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 95 Middle East & Africa: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 96 Middle East & Africa: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 97 Middle East & Africa: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 98 UAE: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 99 UAE: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 100 UAE: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 101 UAE: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 102 Saudi Arabia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 103 Saudi Arabia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 104 Saudi Arabia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 105 Saudi Arabia: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 106 South Africa: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 107 South Africa: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 108 South Africa: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 109 South Africa: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • Table 110 Israel: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • Table 111 Israel: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • Table 112 Israel: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • Table 113 Israel: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)

List of Figures

Figure 1. Global Migraine Drugs Market, 2018 - 2030 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up End-Use

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Product Type

Figure 7. Global Migraine Drugs Market, by Product Type, 2021 & 2030 (USD Billion)

Figure 8. Market by End-Use

Figure 9. Global Migraine Drugs Market, by End-Use, 2021 & 2030 (USD Billion)

Figure 10. Market by Therapeutic Class

Figure 11. Global Migraine Drugs Market, by Therapeutic Class, 2021 & 2030 (USD Billion)

Figure 12. Market by Route of Administration

Figure 13. Global Migraine Drugs Market, by Route of Administration, 2021 & 2030 (USD Billion)

Figure 14. Migraine Drugs Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 15. Strategic Analysis - Migraine Drugs Market

目次
Product Code: PM1391

The global Migraine Drugs market size is expected to reach USD 8.79 billion by 2030, according to a new study by Polaris Market Research. The report "Migraine Drugs Market Share, Size, Trends, Industry Analysis Report, By Product Type (Acute/Abortive Treatment, Preventive/Prophylactic Treatment); By Therapeutic Class; By Route of Administration; By End-Use; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The increasing prevalence of neurological illnesses such as migraine among the teenage population as a result of a more sedentary lifestyle is expected to boost the market growth in the future years.

For instance, according to the National Institute of Health, Migraine affects about one billion people worldwide each year and is one of the most frequent neurologic illnesses, with a higher incidence and morbidity, especially among young people and females. From 1990 to 2019, the worldwide age-standardized frequency of migraine grew by 1.7%, with 1.1 billion prevalent instances in 2019.

Moreover, the increasing launch of Calcitonin gene-related peptide (CGRP)-based medicines and significant unmet requirements are some of the important reasons driving market expansion. For instance, in December 2019, Ubrelvy (ubrogepant) tablets were approved by the Food and Drug Administration for the acute (immediate) therapy of migraine, either with or without vision in adults.

Ubrelvy is not approved for the prevention of migraines. It is the first medicine licensed for the acute treatment of migraines in the category of oral calcitonin gene-related peptides (CGRP) antagonists. Thus, this rising prevalence, along with the increasing approvals, is driving market growth over the forecast period.

Furthermore, an increase in females number and a rise in patient awareness about migraine prevention and treatment are major drivers driving the market growth. Migraine headaches are more common in women than in men. According to the National Institute of Health of Migraine Association of Ireland, the global population in 2018 had a female migraineur to male migraineur ratio of 3:1. This is due to variations in estrogen levels in females, particularly during menstruation.

Furthermore, hormonal drugs, including oral contraceptives and hormone replacement treatment, may aggravate migraine in women. As a result, an increase in the worldwide female population is expected to drive the market growth of the migraine drugs.

Migraine Drugs Market Report Highlights

Online pharmacy segment is expected to grow at a significant CAGR over the forecast period. It is the quickest segment, offering migraine drugs through e-commerce platforms. The majority of the drugs given by online pharmacy chains are for the treatment of severe migraines.

Preventive/ Prophylactic Treatment segment accounted for a lucrative revenue share. Migraine prevention methods lessen migraine frequency and severity. Beta-blockers, botulism toxin toxins, and topiramate are the main pharmacological types used in preventive therapy.

Asia Pacific is expected to grow at a significant CAGR over the projected period. The Asia Pacific region is expected to grow significantly in the future, due to increased demand for improved health centers and improvements in the healthcare system.

The global players include Allergan, Alder Biopharmaceuticals, AstraZeneca, Amgen Inc., eNeura Inc., Eli Lilly and Company, GlaxoSmithKline, Johnson & Johnson, Merck, Pfizer, and Teva Pharmaceutical.

Polaris Market Research has segmented the migraine drugs market report based on product type, therapeutic class, end-use, route of administration, and region:

Migraine Drugs, Product Type Outlook (Revenue - USD Billion, 2018 - 2030)

Acute / Abortive Treatment

Preventive/ Prophylactic Treatment

Migraine Drugs, Therapeutic Class Outlook (Revenue - USD Billion, 2018 - 2030)

Triptans

Acetylcholine Inhibitors/ neurotoxins

Ergot Alkaloids

NSAIDs

Ditans

CGRP small molecule antagonists

CGRP monoclonal antibodies

Others

Migraine Drugs, Route of Administration Outlook (Revenue - USD Billion, 2018 - 2030)

Oral

Injectables

Others

Migraine Drugs, End-Use Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital pharmacies

Retail pharmacies

Online pharmacies

Migraine Drugs, Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S

Canada

Europe

Germany

UK

France

Italy

Spain

Russia

Netherlands

Asia Pacific

China

India

Japan

South Korea

Indonesia

Malaysia

Latin America

Argentina

Brazil

Mexico

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Sources
    • 3.2.1. Primary Sources
    • 3.2.2. Secondary Sources

4. Global Migraine Drugs Market Insights

  • 4.1. Migraine Drugs - Industry Snapshot
  • 4.2. Migraine Drugs Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increase in prevalence of migraine
      • 4.2.1.2. Rise in awareness among patients toward migraine treatment and prevention
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Side effects of migraine drug
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTLE Analysis
  • 4.5. Migraine Drugs Industry Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Migraine Drugs Market, by Product Type

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
  • 5.3. Acute/Abortive Treatment
    • 5.3.1. Global Migraine Drugs Market, by Acute/Abortive Treatment, by Region, 2018 - 2030 (USD Billion)
  • 5.4. Preventive/ Prophylactic Treatment
    • 5.4.1. Global Migraine Drugs Market, by Preventive/ Prophylactic Treatment, by Region, 2018 - 2030 (USD Billion)

6. Global Migraine Drugs Market, by Therapeutic Class

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
  • 6.3. Triptans
    • 6.3.1. Global Migraine Drugs Market, by Triptans, by Region, 2018 - 2030 (USD Billion)
  • 6.4. Acetylcholine Inhibitors/ neurotoxins
    • 6.4.1. Global Migraine Drugs Market, by Acetylcholine Inhibitors/ neurotoxins, by Region, 2018 - 2030 (USD Billion)
  • 6.5. Ergot Alkaloids
    • 6.5.1. Global Migraine Drugs Market, by Ergot Alkaloids, by Region, 2018 - 2030 (USD Billion)
  • 6.6. NSAIDs
    • 6.6.1. Global Migraine Drugs Market, by NSAIDs, by Region, 2018 - 2030 (USD Billion)
  • 6.7. Ditans
    • 6.7.1. Global Migraine Drugs Market, by Ditans, by Region, 2018 - 2030 (USD Billion)
  • 6.8. CGRP small molecule antagonists
    • 6.8.1. Global Migraine Drugs Market, by CGRP small molecule antagonists, by Region, 2018 - 2030 (USD Billion)
  • 6.9. CGRP monoclonal antibodies
    • 6.9.1. Global Migraine Drugs Market, by CGRP monoclonal antibodies, by Region, 2018 - 2030 (USD Billion)
  • 6.10. Others
    • 6.10.1. Global Migraine Drugs Market, by Others, by Region, 2018 - 2030 (USD Billion)

7. Global Migraine Drugs Market, by Route of Administration

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 7.3. Oral
    • 7.3.1. Global Migraine Drugs Market, by Oral, by Region, 2018 - 2030 (USD Billion)
  • 7.4. Injectables
    • 7.4.1. Global Migraine Drugs Market, by Injectables, by Region, 2018 - 2030 (USD Billion)
  • 7.5. Others
    • 7.5.1. Global Migraine Drugs Market, by Others, by Region, 2018 - 2030 (USD Billion)

8. Global Migraine Drugs Market, by End-Use

  • 8.1. Key Findings
  • 8.2. Introduction
    • 8.2.1. Global Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
  • 8.3. Hospital pharmacies
    • 8.3.1. Global Migraine Drugs Market, by Hospital pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 8.4. Retail pharmacies
    • 8.4.1. Global Migraine Drugs Market, by Retail pharmacies, by Region, 2018 - 2030 (USD Billion)
  • 8.5. Online pharmacies
    • 8.5.1. Global Migraine Drugs Market, by Online pharmacies, by Region, 2018 - 2030 (USD Billion)

9. Global Migraine Drugs Market, by Geography

  • 9.1. Key findings
  • 9.2. Introduction
    • 9.2.1. Migraine Drugs Market Assessment, By Geography, 2018 - 2030 (USD Billion)
  • 9.3. Migraine Drugs Market - North America
    • 9.3.1. North America: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
    • 9.3.2. North America: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.3.3. North America: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
    • 9.3.4. North America: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.3.5. Migraine Drugs Market - U.S.
      • 9.3.5.1. U.S.: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.3.5.2. U.S.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.3.5.3. U.S.: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.3.5.4. U.S.: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.3.6. Migraine Drugs Market - Canada
      • 9.3.6.1. Canada: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.3.6.2. Canada: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.3.6.3. Canada: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.3.6.4. Canada: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.4. Migraine Drugs Market - Europe
    • 9.4.1. Europe: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
    • 9.4.2. Europe: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.4.3. Europe: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
    • 9.4.4. Europe: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.5. Migraine Drugs Market - UK
      • 9.4.5.1. UK: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.5.2. UK: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.5.3. UK: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.5.4. UK: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.6. Migraine Drugs Market - France
      • 9.4.6.1. France: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.6.2. France: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.6.3. France: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.6.4. France: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.7. Migraine Drugs Market - Germany
      • 9.4.7.1. Germany: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.7.2. Germany: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.7.3. Germany: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.7.4. Germany: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.8. Migraine Drugs Market - Italy
      • 9.4.8.1. Italy: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.8.2. Italy: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.8.3. Italy: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.8.4. Italy: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.9. Migraine Drugs Market - Spain
      • 9.4.9.1. Spain: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.9.2. Spain: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.9.3. Spain: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.9.4. Spain: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.10. Migraine Drugs Market - Netherlands
      • 9.4.10.1. Netherlands: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.10.2. Netherlands: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.10.3. Netherlands: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.10.4. Netherlands: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.4.11. Migraine Drugs Market - Russia
      • 9.4.11.1. Russia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.4.11.2. Russia.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.4.11.3. Russia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.4.11.4. Russia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.5. Migraine Drugs Market - Asia Pacific
    • 9.5.1. Asia Pacific: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
    • 9.5.2. Asia Pacific: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.5.3. Asia Pacific: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
    • 9.5.4. Asia Pacific: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.5. Migraine Drugs Market - China
      • 9.5.5.1. China: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.5.2. China.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.5.3. China: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.5.4. China: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.6. Migraine Drugs Market - India
      • 9.5.6.1. India: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.6.2. India.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.6.3. India: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.6.4. India: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.7. Migraine Drugs Market - Japan
      • 9.5.7.1. Japan: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.7.2. Japan.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.7.3. Japan: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.7.4. Japan: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.8. Migraine Drugs Market - Malaysia
      • 9.5.8.1. Malaysia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.8.2. Malaysia.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.8.3. Malaysia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.8.4. Malaysia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.9. Migraine Drugs Market - Indonesia
      • 9.5.9.1. Indonesia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.9.2. Indonesia.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.9.3. Indonesia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.9.4. Indonesia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.5.10. Migraine Drugs Market - South Korea
      • 9.5.10.1. South Korea: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.5.10.2. South Korea.: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.5.10.3. South Korea: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.5.10.4. South Korea: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.6. Migraine Drugs Market - Middle East & Africa
    • 9.6.1. Middle East & Africa: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
    • 9.6.2. Middle East & Africa: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.6.3. Middle East & Africa: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
    • 9.6.4. Middle East & Africa: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.5. Migraine Drugs Market - Saudi Arabia
      • 9.6.5.1. Saudi Arabia: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.6.5.2. Saudi Arabia: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.5.3. Saudi Arabia: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.6.5.4. Saudi Arabia: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.6. Migraine Drugs Market - South Africa
      • 9.6.6.1. South Africa: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.6.6.2. South Africa: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.6.3. South Africa: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.6.6.4. South Africa: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.7. Migraine Drugs Market - Israel
      • 9.6.7.1. Israel: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.6.7.2. Israel: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.7.3. Israel: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.6.7.4. Israel: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.6.8. Migraine Drugs Market - UAE
      • 9.6.8.1. UAE: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.6.8.2. UAE: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.6.8.3. UAE: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.6.8.4. UAE: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.7. Migraine Drugs Market - Latin America
    • 9.7.1. Latin America: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
    • 9.7.2. Latin America: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
    • 9.7.3. Latin America: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
    • 9.7.4. Latin America: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.5. Migraine Drugs Market - Mexico
      • 9.7.5.1. Mexico: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.7.5.2. Mexico: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.7.5.3. Mexico: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.7.5.4. Mexico: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.6. Migraine Drugs Market - Brazil
      • 9.7.6.1. Brazil: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.7.6.2. Brazil: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.7.6.3. Brazil: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.7.6.4. Brazil: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)
    • 9.7.7. Migraine Drugs Market - Argentina
      • 9.7.7.1. Argentina: Migraine Drugs Market, by Product Type, 2018 - 2030 (USD Billion)
      • 9.7.7.2. Argentina: Migraine Drugs Market, by End-Use, 2018 - 2030 (USD Billion)
      • 9.7.7.3. Argentina: Migraine Drugs Market, by Therapeutic Class, 2018 - 2030 (USD Billion)
      • 9.7.7.4. Argentina: Migraine Drugs Market, by Route of Administration, 2018 - 2030 (USD Billion)

10. Competitive Landscape

  • 10.1. Expansion and Acquisition Analysis
    • 10.1.1. Expansion
    • 10.1.2. Acquisitions
  • 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

  • 11.1. Allergan Plc
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Benchmarking
    • 11.1.4. Recent Development
  • 11.2. Alder Biopharmaceuticals Inc.
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Benchmarking
    • 11.2.4. Recent Development
  • 11.3. AstraZeneca PLC
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Benchmarking
    • 11.3.4. Recent Development
  • 11.4. Amgen Inc
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Benchmarking
    • 11.4.4. Recent Development
  • 11.5. eNeura Inc
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Benchmarking
    • 11.5.4. Recent Development
  • 11.6. Endo Pharmaceuticals Inc
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Benchmarking
    • 11.6.4. Recent Development
  • 11.7. Eli Lilly and Company
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Benchmarking
    • 11.7.4. Recent Development
  • 11.8. GlaxoSmithKline Plc
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Benchmarking
    • 11.8.4. Recent Development
  • 11.9. Johnson & Johnson Services Inc
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Benchmarking
    • 11.9.4. Recent Development
  • 11.10. Merck & Co. Inc
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Benchmarking
    • 11.10.4. Recent Development
  • 11.11. Pfizer Inc
    • 11.11.1. Company Overview
    • 11.11.2. Financial Performance
    • 11.11.3. Product Benchmarking
    • 11.11.4. Recent Development
  • 11.12. Teva Pharmaceutical Industries Ltd
    • 11.12.1. Company Overview
    • 11.12.2. Financial Performance
    • 11.12.3. Product Benchmarking
    • 11.12.4. Recent Development